The ability to provide targeted therapeutic delivery in the lung would be a major advancement in pharmacological treatments for many pulmonary diseases. Critical issues for such successful delivery would require the ability to target specific cell types, minimize toxicity (e.g., inflammatory response), and deliver therapeutic levels of drugs. We report here on the ability of nanoconjugates of CdSe/CdS/ZnS quantum dots (QDs) and doxorubicin (Dox) to target alveolar macrophages (aMØs), cells that play a critical role in the pathogenesis of inflammatory lung injuries. Confocal imaging showed the release of Dox from the QD-Dox nanoconjugate, as was evident by its accumulation in the cell nucleus and induction of apoptosis, implying that the drug retains its bioactivity after coupling to the nanoparticle. Inflammatory injury parameters (albumin leakage, proinflammatory cytokines, and neutrophil infiltration) were recorded after in vivo administration of QD-Dox and Dox, observing no significant effect after QD-Dox treatment compared with Dox. These results demonstrate that nanoparticle platforms can provide targeted macrophage-selective therapy for the treatment of pulmonary disease.
Immune-inflammatory modulation is important in various pulmonary disease processes including asthma, acute respiratory distress syndrome, and chronic obstructive pulmonary disease. The creation of stable, site-specific, therapeutic delivery platforms to direct drugs to a specific cellular target can tightly control therapy and reduce "collateral damage." This is important for an immune-inflammatory therapy, where there is a constant balance between the beneficial effects of down-modulating an overactive immune response, while increasing the risk posed by suppressed immunity.
The alveolar macrophage (aMØ) is the sentinel cell involved in directing the host innate and participates in adaptive immune responses involved in infectious and noninfectious lung diseases. The aMØ's central role in response to environmental influences makes these cells a candidate for targeted drug delivery in the modulation of the immune-inflammatory response. The potential for inhalational administration makes the lungs a unique target for drug-nanoconjugate therapy.
We hypothesize that aMØs can be selectively targeted by doxorubicin (Dox) coupled to quantum dots (QDs). QDs are composed of atoms from groups II-VI or III-V or IV of the periodic table, and have a size comparable to or smaller than the Bohr radius. 1, 2 This size leads to a quantum confinement effect, which results in size-dependent optical properties. Furthermore, the QDs' surfaces are easy to functionalize to provide support for covalent coupling of therapeutic agents. 1, 3, 4 We report here the successful use of colloidally synthesized cadmium selenidecadmium sulfide-zinc sulfide (CdSe/CdS/ZnS) QDs 5, 6 for the delivery of Dox to lung aMØs.
Methods

QD-Dox synthesis
CdSe/CdS/ZnS QDs were prepared by growing a CdS/ZnSgraded shell on a CdSe core. The detailed protocol for QD preparation used in these studies was described by our laboratory.
Formation of the QD-Dox nanoconjugate was accomplished by combining 30 μL of QDs (∼1.41 × 10 -12 mol) and 20 μL of triethylamine (∼1 × 10 -7 mol) with 203 μL of HPLC-grade water, followed by 67 μL of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (∼1.68 × 10 -7 mol) and mixing for several minutes. Then, 7 μL of Dox (∼3.02 × 10 -8 mol) were added and the mixture incubated for 2-4 hours; the reddish solution was centrifuged at 9900 g for 30 minutes. The pellets were washed once with water, and the QD-Dox nanoconjugates were redispersed in water to a final volume of 330 μL (4.3 × 10 -5 mol/μL). The conjugation efficiency of 47% was determined by spectrometry (absorption at 482 nm). [7] [8] [9] QD-Dox nanoconjugate parameters including surface charge, size, and photoluminescence were measured as described by Yong.
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Animal model
Male Long-Evans rats (250-300 g) and C57BL/6 mice (25-30 g) were obtained from Harlan Sprague-Dawley (Indianapolis, Indiana) and Charles River Laboratories (Wilmington, Massachusetts), respectively. The Institutional Animal Care and Use Committee of the Veterans Administration Western New York Healthcare System in Buffalo approved all experiments, and all animal work conformed to their guidelines for the humane care of animals.
Oropharyngeal aspiration delivery of nanoparticle solutions to the lungs
Rats and mice were anesthetized with 2% halothane in oxygen and, when unresponsive to a toe pinch, suspended by their incisors in a 60-degree supine position. The tongue was pulled out forward to raise the epiglottis, thereby opening the laryngeal inlet. Before solution instillation, the chest was squeezed and, following deposition of 300 μL (95 µL for mice) of the solution into the oropharynx with a pipette, released to facilitate aspiration of the instillate into the alveoli. A second 300 μL aliquot was instilled into the lungs 1 minute later. The following instillate solutions were used: (i) water (H 2 O, vehicle control), (ii) 10 nM Dox in H 2 O, (iii) 10 nM equivalent of QDDox based on equivalent fluorescence emission at 570 nm. Animals were killed 4 or 24 hours after instillation, with a minimum of two rats per time point per instillate group being performed during each experiment that was repeated three times (n = 6 for each treatment and time point).
Arterial blood gas measurements
Arterial oxygenation (PaO 2 ) was measured in blood collected from the abdominal aorta following 2% halothane in 98% O 2 for 5 minutes and analyzed with an ABL5 blood gas analyzer (Radiometer America, Westlake, Ohio).
Bronchoalveolar lavage
The bronchoalveolar lavage (BAL) fluid was collected according with the protocol optimized by Knight et al. 10 BAL fluid albumin and cytokine enzyme-linked immunosorbent assay (ELISA)
The degree of pulmonary injury was assessed by measuring the leakage of albumin into the airspaces following the procedure of Nemzek et al. 11 Concentrations of the biomarkers MCP-1, MIP-2, and CINC-1 (see below) in BAL fluid were determined with commercially available ELISA kits from R & D Systems (Minneapolis, Minnesota) or PharMingen (San Diego, California) following the manufacturers' instructions.
BAL fluid tumor necrosis factor-α (TNFα WEHI bioassay)
TNFα bioactivity was measured using the WEHI-164 subclone 13 fibrosarcoma cell line bioassay, as described. 11, 12 BAL fluid differential cell count Following centrifugation of the collected BAL fluid, the cell pellet was processed according with the protocol optimized by Knight et al. 10 
Histopathological analysis
Following in situ flushing of the pulmonary vasculature, the trachea was cannulated, and the lungs were inflated at 20 cm H 2 O with 10% neutral buffered formalin while suspended in 10% neutral buffered formalin and incubated for ∼24 hours at 20°C-22°C. Transverse sections, 2-3 mm thick, were prepared from the left lung and from each of the four right lung lobes and embedded in paraffin; 4 μm sections were stained with hematoxylin and eosin. Slides were coded to "blind" the pathologist.
Alveolar macrophage cell isolation and in vitro nanoparticle exposure BAL was performed on naive rats, the fluid centrifuged, and the cell pellet (N95% aMØs) resuspended in RPMI-1640 containing 1 mM glutamine, penicillin and streptomycin, amphotericin B, and 10% fetal bovine serum to 1 × 10 6 aMØs/ mL. 200 μL/well (2 × 10 5 cells) were dispensed into wells of a low-binding, 96-well, flat-bottomed culture plate (Nunc; Thermo Fisher Scientific, Rochester, New York) and incubated at 37°C, 90% relative humidity (RH), 5% CO 2 for 20 hours. The cells were resuspended in 100 μL fresh medium and exposed to 20 μL of Dox or QD-Dox at 37°C, 90% RH, 5% CO 2 for 4 and 24 hours on a rocking-rotating platform (Nutator; TCS Scientific, New Hope, Pennsylvania). The supernatant was collected for cytokine analyses. The cells were washed and resuspended in 300 μL of 2% bovine serum albumin in phosphate-buffered saline + 0.1% sodium azide for cytometric analysis.
For phagocytic assays, 10.5 μL of 100 μg/mL cytochalasin D (Sigma Chemical, St. Louis, Missouri) were added to each well (5 μg/mL final concentration) following the 20-hour incubation. The cell suspensions were washed in either culture medium or serum-free medium (Macrophage Serum-Free Medium; GIBCO, Invitrogen, Carlsbad, California) containing 5.6 μg/mL cytochalasin D. Following centrifugation at 1500 × g for 3 minutes at 4°C, the cell pellets were resuspended in 180 μL fresh medium containing 5.6 μg/mL cytochalasin D and transferred to wells of a low-binding, 96-well, flat-bottomed culture plate. Dox, QDDox, or H 2 O (20 μL/well) was added, and the cells were incubated and analyzed by flow cytometry.
Confocal microscopic analysis
The aMØs and BAL-recovered cells were dispensed onto a 35-mm glass-bottom microwell dish (MatTek, Ashland, Massachusetts) and treated with 200 μL of medium, Dox, or QD-Dox solutions. Confocal images were obtained at 4 and 24 hours postexposure using a Leica confocal microscopy system (TCS SP2; Leica Microsystems, Bannockburn, Illinois) with an oil immersion objective (HXC PL APO CS 63×1.40). Hoechst 33342 was added to stain the nuclei and was imaged using a 405 nm laser while the fluorescence emission was collected at 430-480 nm. A 488 nm laser was applied to excite both Dox and the QDs. The fluorescence signal from Dox was collected at 540-580 nm, while the photoluminescence signal from the QDs was collected at 620-660 nm. For emission spectrum analysis a 10-nm band-pass filter was used, and the scan was acquired from 500 nm to 700 nm in 10-nm steps.
Flow cytometry
aMØ staining was assessed using a FACS Calibur flow cytometer (BD Biosciences, San Jose, California) with the acquisition threshold set using the forward-scatter detector to exclude noncellular events (i.e., cell debris). The fluorescence emissions of 10,000 cell events were collected with the FL2 (excitation = 488 nm, emission = 585 ± 21 nm optimized for Dox) and FL3 (excitation = 488 nm, emission = 661 ± 8 nm optimized for QD) detectors. QD-labeled aMØs exhibited no spectral overlap into the FL2 emission window. The label negative/positive boundary was set using the H 2 O-treated aMØ samples such that ∼99% was label-negative.
WST-1 reduction assay
Following the overnight incubation, the aMØ culture was washed with warm phosphate-buffered saline, and 200 μL/well of warm culture medium containing the appropriate test solution were added. The culture was incubated at 37°C, 90% RH, 5% CO 2 on a rocking platform for 4 or 24 hours. Three hours before harvest, 10 μL of WST-1 Cell Proliferation Reagent (Roche Diagnostics, Indianapolis, Indiana) were added to appropriate wells. Following transfer to a clean 96-well plate, the absorbance was measured at 440 and 700 nm in a SpectraMax 190 microplate spectrophotometer (Molecular Devices, San Diego, California). The absorbance difference between 700 nm and 440 nm is proportional to the culture viability.
Statistical analysis
All data were expressed as mean ± SEM. Comparisons of the assayed parameters at each harvest time point (4 and 24 hours) between the experimental and control groups (n = 6 per group) were made using one-way analysis of variance and Tukey's post-hoc tests.
Results
QD-Dox nanoconjugate
Dynamic light scattering indicated that the hydrodynamic diameter of the QDs was 11.1 ± 0.2 nm and 30.7± 2.9 nm for QD- Figure 3 . Effect of free Dox and QD-Dox on in vitro cytokine production in primary rat aMØs. Rat aMØs were isolated by BAL and exposed in vitro for 4 or 24 hours to Dox, QD-Dox, or 1.5 μg/mL LPS in a 96-well culture plate. Culture medium was assayed for (A) TNFα using the WEHI bioassay, and (B) MIP-2, (C) CINC-1, and (D) MCP-1 by ELISA. Only exposure to LPS produced a significant response of each cytokine or chemokine at both time points compared to unexposed aMØs, *P b 0.01. Dox. The change in the hydrodynamic diameter after coupling is indicative of the surface presence of Dox. Covalent coupling was determined by a shift in zeta potential from -38.38 ± 2.3 mV (QDs) to -15.42 ± 0.3 mV (QD-Dox), indicating the formation of amide bonds between the amine group of the Dox and the carboxyl groups on the QD surface.
aMØ uptake of the QD-Dox
The uptake of Dox vs. QD-Dox was determined by flowcytometric analysis of aMØs after 1, 6, and 24 hours in vitro after exposure. In Figure 1 , A, the percentages of cells positive for free Dox were 4.5 ± 0.1%, 15.1 ± 0.6%, 26.5 ± 0.8% at 1, 6, and 24 hours, respectively. Following QD-Dox exposure, 15.7 ± 0.5%, 31.5 ± 1.4%, and 59.7 ± 0.8% of aMØs were positive, demonstrating significant increases (P b 0.0004) at each of the respective time points over the Dox-only groups. Thus, coupling of Dox to the QDs enhances uptake of the drug by the aMØs. Figure 1 , B is a confocal image of primary rat aMØs acquired 3 hours after exposure to the QD-Dox, in vitro. Using separate acquisition channels for Dox (pseudo-green) and QDs (pseudored), we observed an accumulation of Dox in the nucleus, whereas the signal from the QDs remained in the cytoplasm, indicating separation. A mechanism of Dox action is its intercalation in DNA, inducing apoptosis. 13, 14 Macrophages treated with QD-Dox show clumping and blebbing, which are signs of apoptosis.
Flow cytometry (Figure 1, C) revealed that cytochalasin D treatment had no effect on Dox uptake, irrespective of the presence of serum in the medium, indicating that the uptake involves an actin polymerization-independent pinocytosis pathway. However, in the presence of serum, QD-Dox uptake was ablated by cytochalasin D, 2.0% ± 0.2% compared with 25.0% ± 2.6% (P b 0.001). In the absence of serum, cytochalasin D, the uptake was reduced from 74.9% ± 1.2% to 45.7% ± 1.1% (P b 0.001), indicating both actin polymerization-dependent (i.e., phagocytosis, macropinocytosis) and -independent (i.e., clathrin-mediated endocytosis, caveolin-mediated endocytosis) pathways are involved. We also compared QD uptake in the presence and absence of cytochalasin D. In serum, the QD uptake dropped from 93.4% ± 1.3% to 58.1% ± 1.2% upon treatment with cytochalasin D, but not in the absence of serum (data not shown). These findings suggest that serum-induced aggregation of QD enhances uptake through phagocytosis, while single suspension conjugated QDs are taken up using an actin polymerization-independent pinocytosis pathway. 15 To determine whether coupling of Dox to QDs retains drug functionality, we performed a WST-1 reduction assay, to assess aMØ viability (Figure 1, B) . At 24 hours post-exposure, there was ∼40% reduction in viability of the aMØs upon exposure to QD-Dox (P b 0.001 [ Figure 2] ). Thus, our drug delivery system using QDs retains drug functionality comparable to treatment with free Dox.
We also assayed the in vitro medium following the exposure of aMØs to QD-Dox for TNFα, the neutrophil chemoattractants CINC-1 and MIP-2 (important in the acute neutrophilic inflammatory response), and the monotactic chemokine MCP-1, a biomarker of later developing monocytic inflammation. Lipopolysaccharide (LPS, 1.5 μg/mL) was employed as a positive control. Exposure to Dox or QD-Dox did not increase TNFα, CINC-1, MIP-2, or MCP-1 amounts as compared to unexposed aMØs at both 4 and 24 hours post-exposure (Figure 3 ). Therefore, free Dox or QD-Dox induces aMØ apoptosis without causing a concurrent proinflammatory cytokine response.
In vivo delivery of QD-Dox by oropharyngeal aspiration
To translate our in vitro findings to in vivo, we delivered the QD-Dox nanoconjugates into the pulmonary airspaces of rats by oropharyngeal aspiration. At 24 hours postinstillation, the cells were recovered by BAL and imaged by confocal microscopy ( Figure 4, A-D) . The presence of QD-Dox in the aMØs was demonstrated with z-stack analysis confirming intracellular translocation (data not shown). Identification of the emitting molecular species was determined by spectral emission analysis (Figure 4, E) . Thus, oropharyngeal aspiration successfully delivered the QD-Dox to aMØs in vivo. Figure 5 demonstrates successful deposition of QDs, with mercaptosuccinic acid (MSA) surface modification, into the lung parenchyma of C57BL/6 mice following oropharyngeal aspiration delivery.
Finally, we examined inflammatory pulmonary injury ( Figure 6 ) by assessing: BAL fluid cytokines ( Figure 6, A-D) ; BAL fluid albumin ( Figure 6, E) ; arterial blood oxygenation ( Figure 6, F) ; BAL fluid leukocyte count (Figure 6 , G) and differential ( Figure 6 , H and I); and histopathology. In vivo, there were no increases in TNFα or MIP-2 at 4 and 24 hours in any of the experimental groups ( Figure 6, A and B) . However, we observed that treatment with Dox produced significant increases in CINC-1 at 4 hours (Figure 6, C) , and the MCP-1 (Figure 6, D) level at 24 hours (P b 0.05). The increased CINC-1 level was consistent with increased neutrophil infiltration into the airways following Dox administration (Figure 6, H) . There was ∼66% more neutrophil infiltration at 4 hours (P b 0.05), and ∼50% more neutrophil infiltration at 24 hours compared with QD-Dox treated rats. Increases in MCP-1 (Figure 6, D) would indicate that Dox induces a sustained inflammatory response. At 4 hours after treatment (Figure 6 , E) the albumin concentration in the airways of animals treated with Dox alone was 88.1 ± 30.6 pg/mL of albumin, whereas the level following QD-Dox was 31 ± 4 pg/mL (P b 0.05). The albumin concentration following the QD-Dox treatment at 4 and 24 hours was comparable to control. Arterial blood oxygen partial pressure/inspired oxygen fraction (PaO 2 / FiO 2 ) decreased to ∼400 mm Hg for both 4 and 24 hours after exposure to Dox compared with ∼590 mm Hg for controls (P b 0.01) (Figure 6, F) . Collectively, these findings demonstrate less inflammatory response and functional lung impairment using QD-Dox compared with Dox.
After instillation, histopathology of lungs at 4 and 24 hours did not demonstrate any differences between the groups that received control, Dox, or QD-Dox. The majority of the pulmonary parenchyma contained normal lung histology with intact alveolar architecture, thin septa, and normal pleura, and the conducting and respiratory airways were normal. A few isolated, focal areas of parenchymal intra-alveolar cellular infiltrates, activated alveolar type II cells, thickened alveolar septa, and minor occurrences of perivascular edema were found. Samples could not be stratified, because all of the injury groups exhibited similar patterns of change.
Discussion
Nanoparticle delivery systems are currently being used for new pharmaceutical moieties, improved drug effectiveness with reduced side effects, and cell-and tissue-specific targeting. 2 We have developed a nanotechnology-based approach for drug delivery to aMØs. The rationale for using QD-Dox is based on the differential photoluminescence of these two agents. This allows for visual confirmation of the intracellular uptake, as well as dissociation of Dox in the nucleus, which is required for drug action. Our in vitro findings demonstrate that QD-Dox enhances intracellular uptake compared with free drug.
Additionally, the uptake of QD-Dox by the aMØs did not elicit a significant proinflammatory cytokine response. We also demonstrate that Dox is released from the QD-Dox formulation and migrates to the nucleus (site of bioactivity), whereas the QDs remain in the cytosol.
Administration of QD-Dox, in vivo, also resulted in uptake into aMØs without any evidence of acute lung injury or increase cytokine levels. A decrease in PaO 2 /FiO 2 occurred at both 4 and Figure 6 . Effect of free Dox and QD-Dox on in vivo pulmonary cytokine production, injury parameters, and cellular inflammatory response. Rats were exposed to H 2 O (control), Dox, or QD-Dox by oropharyngeal aspiration. At 4 or 24 hours after exposure an arterial blood sample was taken and BAL performed. The recovered BAL fluid was assayed for (A) TNFα bioactivity by WEHI bioassay, and (B) MIP-2, (C) CINC-1, and (D) MCP-1 by ELISA. Lung injury was assessed by (E) BAL albumin by ELISA, and (F) PaO 2 /FiO 2 . The pulmonary cellular inflammatory response was assessed by (G) total number of leukocytes, (H) neutrophils, and (I) aMØs recovered in the BAL fluid. *P b 0.05 compared to the H 2 O control group. 24 hours following Dox administration, which was associated with increased levels of proinflammatory cytokines, and leakage of albumin and neutrophils into the airways. This decrease was not observed with QD-Dox, indicating that injury resulting from the administration of Dox was mitigated by conjugating Dox to QDs. Finally, histopathology studies after oropharyngeal instillation found only minimal abnormalities. Collectively, these findings demonstrate a novel drug delivery method targeting aMØs in vivo, with no discernible lung injury.
Previous reports have employed large porous particles 16 or large polymeric particles 17 for targeting cells within the lung alveolus. However, QDs as a carrier system present distinct advantages of having both diagnostic and therapeutic benefits. 18 The ease of formulation and uniformity of QDs make a more efficient approach to lung cell targeting. Several studies have also assessed polysorbate-coated nanoparticles 19 and polyalkylcyanoacrylate 20 nanoparticles loaded with Dox. These reports also demonstrated a therapeutic efficacy and decreased toxicity compared with the nonconjugated drug, consistent with our observations.
Our approach for targeting of aMØs is based on their role as a scavenger of small particles that enter the alveoli. Uptake of "dust" particles does not usually elicit an inflammatory response. Previous studies reported that aMØs possess receptors for polyanionic particles 21 that enable them to take up negatively charged particles more efficiently than neutral and positive ones. Both the size of the QD and composition of the solution used appear to be critical in the aMØ uptake mechanism. Uptake in serum was clearly dependent on a phagocytic mechanism and in the absence of serum, non-actin polymerization-requiring pinocytic process(es).
The efficient scavenging of QD-Dox by the aMØs provides a compelling mechanism for the prevention of injury to other cells of the lung by Dox. The observed BAL fluid cytokine levels following QD-Dox exposure are indistinguishable from those obtained from control animals. It is reasonable to speculate that decreases in inflammatory lung injury are directly related to a decrease of other cells of airways and alveoli to which there is free Dox uptake.
The potential of using a nanoparticle drug delivery approach provides a novel therapeutic strategy for treating lung diseases. The ability to target specific cells in the lung without exposing other pulmonary tissue or distant organs to detrimental actions of drugs is an exciting avenue to explore. Many of the complications associated with immune-inflammatory therapy are caused by the inability to limit life-threatening systemic responses. Potential applications could lead to therapeutic strategies to selectively upregulate and downregulate key aMØ regulatory and effector functions. Our study has shown that QDs can also serve as a diagnostic resource with minimal toxicity regionally and systemically. 22 However, we must acknowledge that ongoing studies must address in greater depth what parameters (i.e., surface coating and functionalization, charge, size, duration of treatment) with QD formulations result in reduced regional and systemic toxicity. We refer the reader to several articles that also address the issue of QD cytotoxicity. 23, 24 Based on our study, we propose that the formulation inclusive of surface coating, as well as side groups are critical in modulating lung injury following instillation. Therefore, MSA QDs may have tremendous potential for diagnosis and treatment of lung injury superior to other formulations primarily because of their selective uptake into aMØs and should be further assessed for future lung pharmacotherapy applications.
